Key result
Intravenous monafram therapy during coronary stenting in STEMI patients resulted in a stent thrombosis rate of 2.75% compared to 3.6% without monafram, with no major bleedings.
Why the study?
Does intravenous monafram therapy improve clinical outcomes and safety in acute STEMI patients undergoing coronary stenting?
Cohort (n=220)
Does intravenous monafram therapy improve clinical outcomes and safety in acute STEMI patients undergoing coronary stenting?
Intravenous monafram during bare-metal stenting for STEMI appears safe and well-tolerated, with low rates of stent thrombosis and no increased bleeding risk.
Answers are grounded in this paper and cite their sources.
May support monafram in STEMI stenting for lower thrombosis without major bleeding; leaves open confirmation in randomized trials.
Aim. To study of efficacy and safety of glycoprotein IIb/IIIa blocker monafram in acute ST-segment elevation myocardial infarction (STEMI) patients, underwent coronary stenting. Material and methods. 220 STEMI patients were included in the trial; they were split into two groups. 109 patients of the first group were underwent coronary stenting with i/v monafram therapy. Coronary stenting without monafram therapy was performed in 111 patients of the second group. Bare metal stents were used in all patients. Deaths, stent thrombosis, individual intolerance, allergic reactions, bleeding were registered during hospitalization. Results. There were 3 (2.75%) cases of stent thrombosis in monafram group and 4 (3.6%) ones - in the control group. Good tolerance of monafram was observed in all patients. There were no allergic reactions, major and minor bleedings. Reinfarction rate was similar in both groups during 30 days observational period. Conclusions. Monafram therapy is effective and safe in acute STEMI patients underwent coronary stenting.
No takes yet. Share an insight, caveat, or question.
Makhiyanova et al. (2011) conducted a cohort in Acute ST-segment elevation myocardial infarction (STEMI) (n=220). Monafram (glycoprotein IIb/IIIa blocker) vs. Coronary stenting without monafram was evaluated on Stent thrombosis during hospitalization. Intravenous monafram therapy during coronary stenting in STEMI patients resulted in a stent thrombosis rate of 2.75% compared to 3.6% without monafram, with no major bleedings.
Synapse has enriched 10 related papers. Consider them for comparative context: